Kornimate/medical-research-clean huggingface dataset:
exercise program in breast cancer patients receiving neoadjuvant chemotherapy

Conditions: Breast Neoplasm; Physical Activity

Summary: the investigators seek to conduct a home based exercise intervention in breast cancer patients whom elect to undergo neoadjuvant chemotherapy. the primary aim of the study is to determine whether breast cancer patients can be enrolled, randomized, retained, and comply with exercise program; and, the feasibility of acquiring, managing and analyzing clinical data.

several national and international agencies recommend exercise participation for all persons following a cancer diagnosis. the current evidence suggests that aerobic exercise training is safe during primary adjuvant therapy and improves cardiopulmonary function and patient related outcomes. cardiopulmonary fitness is highly predictive of overall and cardiovascular specific mortality in women. specifically, an increase in cardiopulmonary fitness of approximately 10% has been associated with a 19% reduction in risk for cv mortality. this is important as breast cancer patients already present at diagnosis with 31% lower cardiopulmonary fitness levels compared to healthy age-matched women. this enhanced risk for cardiovascular mortality in breast cancer patients is further compounded by cardiotoxic chemotherapy, which causes permanent cardiac damage. few studies have tested the efficacy of exercise prescriptions that incorporate high intensity aerobic exercise training in cancer patients, especially those receiving chemotherapy. therefore, the investigators seek to conduct an at home aerobic exercise training intervention in breast cancer patients whom elect to undergo neoadjuvant chemotherapy

Eligibility criteria:
3.1 inclusion criteria * women with a breast cancer diagnosis (stage i-iiic) * sedentary (\< 75 min/wk of moderate intensity exercise over the past month) * no previous history of anthracycline based chemotherapy * absence of heart disease (clinical diagnosis of coronary artery disease, arrhythmias, congenital heart defects, dilated cardiomyopathy, or valvular heart disease) * absence of contraindications for neoadjuvant chemotherapy * scheduled to receive neoadjuvant chemotherapy * primary attending oncologist approval 3.2 exclusion criteria * absolute contraindications for exercise stress testing * acute myocardial infarction (3-5 days) * unstable angina * uncontrolled arrhythmias causing symptoms or hemodynamic compromise * syncope * acute endocarditis * acute myocarditis or pericarditis * uncontrolled heart failure * acute pulmonary embolus or pulmonary infarction * thrombosis of lower extremities * suspected dissecting aneurysm * uncontrolled asthma * pulmonary edema * room air desaturation at rest ≤85% * respiratory failure * acute noncardiopulmonary disorder that may affect exercise performance or be aggravated by exercise * mental impairment leading to inability to cooperate * decisional impairment * non-english speaking * women only diagnosed with ductal carcinoma in situ * women diagnosed with stage 4 metastatic breast cancer * pregnant women * men * children
the effects of diet and exercise interventions in peripheral artery disease

Conditions: Claudication; Peripheral Artery Disease

Summary: this study is a 3-month, prospective, randomized controlled clinical trial designed to address the efficacy of the dash dietary program combined with a home-based exercise program, quantified by a step activity monitor, to improve exercise and vascular outcome measures in patients with pad.

this study seeks to (1) compare the changes in 6-minute walk distance (6mwd) and physical function quality of life in patients with peripheral artery disease (pad) following a combined intervention of the dietary approaches to stop hypertension (dash) dietary program plus a home-based exercise program, and following a home-based exercise program alone; and (2) compare the changes in microvascular function and inflammation in patients following the combined dash diet and home-based exercise program, and the home-based exercise program alone. the investigators hypothesize that the combined dash diet and exercise program will result in greater increases in 6mwd and in the physical function quality of life than the exercise program alone. further, it is hypothesized that the combined dash diet and exercise program will result in greater improvements in calf muscle oxygen saturation \[sto2\] following exercise, and in high-sensitivity c-reactive protein (hscrp\]) than the exercise program alone. the home-based exercise program consists of intermittent walking to moderate claudication pain in a home-based setting. the dash dietary program consists of the dietary approaches to stop hypertension diet emphasizing foods rich in fruits, vegetables, whole grains, and low-fat dairy.

Eligibility criteria:
inclusion criteria: 1. history of claudication, 2. presence of pad, defined by meeting at least one of the following criteria (abi at rest \ 20% decrease in abi following a heel-rise exercise test in patients with a normal abi at rest (\> 0.90), or history of peripheral revascularization. exclusion criteria: 1. absence of pad, defined by meeting all of the following 3 criteria (abi at rest \> 0.90), \< 20% decrease in abi following a heel-rise exercise test, and no history of peripheral revascularization, 2. non-compressible vessels (abi \> 1.40), 3. rest pain due to pad (fontaine stage iii; rutherford grade ii), 4. tissue loss due to pad (fontaine stage iv; rutherford grade iii), 5. use of medications indicated for the treatment of intermittent claudication (cilostazol and pentoxifylline) initiated within three months prior to investigation, 6. peripheral revascularization within one month prior to investigation, 7. active cancer, 8. end stage renal disease defined as stage 5 chronic kidney disease, 9. medical conditions that are contraindicative for exercise according to the american college of sports medicine, 10. cognitive dysfunction (mini-mental state examination score \< 24), and 11. failure to complete the baseline tests within three weeks.
autologous tenocyte implantation in patients with chronic achilles tendinopathy

Conditions: Tendinopathy; Achilles Tendon Injury; Achillodynia

Summary: this study is designed to compare the treatment of 2 groups in patients with achilles tendinopathy: autologous tenocytes injection in combination with exercises versus saline injection in combination with exercises

overuse injury of the achilles tendon is a common entity. when the exact origin of tendon pain is unclear, the term tendinopathy is preferred. most accepted treatment at this moment is an eccentric exercise programme, according to the dutch guidelines. however, a recent systematic review on the effectiveness of eccentric exercises to treat lower extremity tendinoses concluded that it is unclear whether eccentric exercises are more effective than other forms of treatment. recent studies described new treatment strategies in tendinopathies, such as the use autologous tenocyte implantation (ati). this treatment option can participate actively in tissue repair processes on cell level. the only published clinical pilot study in tendon research reported 60% improvement in all scores after 6 months follow-up.

Eligibility criteria:
inclusion criteria: * pain on palpation 2-7 cm proximal from the tendon insertion ("midportion") * symptoms \> 2 months * age 18-55 years exclusion criteria: * clinical suspicion of insertional disorders , achilles tendon rupture, plantar flexor tenosynovitis, sural nerve pathology, peroneal subluxation * condition of the achilles tendon caused by medications such as quinolones and statins * known to have the following disorders: spondylarthropathy, gout, hyperlipidemia, rheumatoid arthritis and sarcoidosis. * antibiotics allergy (aminoglycoside group) * a condition that prevents the patients from executing an active rehabilitation programme * patient has received an injection for this injury * patient has received surgical intervention for this injury * patient has already one site (left or right) included in this study * patient does not wish, for whatever reason, to undergo one of the two treatments * known pregnancy * nursing women

Keywords: autologous tenocytes cell therapy eccentric exercises
efficacy of mucipliq on the incidence of radio-chemotherapy-induced mucositis in patients suffering from oral cancer

Conditions: Oral Mucositis; Carcinoma in Situ of Upper Respiratory Tract

Summary: mucipliq is a nanopolymer engineered to mimic glycosaminoglycans such as heparan sulfates. glycosaminoglycans are involved 1) in the stabilization of cells micro-environment, known as extracellular matrix, by binding to structural proteins, and 2) in cells communication process by protecting growth factors. at the site of a lesion, glycosaminoglycans are degraded, thereby the extracellular matrix is disorganized and the tissue is destroyed. by replacing damaged glycosaminoglycans, mucipliq provides a protection, and restores the matrix scaffold and cells communication, a process known as matrix therapy. the purpose of this new controlled study is to determine whether mucipliq can decrease the incidence and the severity of radio-chemotherapy-induced mucositis in patients suffering of upper aerodigestive tract cancers, when used as a preventive agent. the study's main hypothesis is that mucipliq mouthwash applications before radiotherapy would protect the healthy oral tissue against cytotoxic effect of chemotherapy and radiations.


Eligibility criteria:
inclusion criteria: * patient suffering from an upper aerodigestive tract carcinoma treated by radiotherapy alone or radiotherapy associated with a concomitant platine-salts-based chemotherapy ; * patient suffering of an upper aerodigestive tract carcinoma without entrance or located in the oral cavity, in the oropharynx or in the rhinopharynx ; * patient age of 18 years old or higher ; * writing informed consent to participate to the trial ; * patient affiliated to the french social security system. exclusion criteria: * treatment by non-standard fragmentation (concentrate irradiation) * carcinoma located in the hypopharynx or in the larynx ; * known hypersensitivity to heparinoids ; * patient who already benefited from a radiotherapy treatment ; * patient who already benefited from a chemotherapy treatment. patients who benefited from neoadjuvant chemotherapy as part of their upper aerodigestive tract carcinoma care, may be included if it was held at least 4 weeks before the inclusion visit ; * patient participating to another biomedical research ; * pregnant woman, breastfeeding woman, parturient or likely to be ; * patient deprived of freedom, under supervision or guardianship ; * patient unable to attend to scheduled medical monitoring due to geographical, social or mental reasons

Keywords: mucipliq matrix therapy rgta oral mucositis
zostavax in persons imminently receiving chemotherapy for solid organ tumors

Conditions: Shingles

Summary: this study evaluates if the shingles vaccine works in those persons that receive it before they receive chemotherapy for solid organ tumors. half of the participants will receive the zostavax shingle vaccine and half of the participants will not received anything.

this study is a single blind randomized clinical trial measuring the immunologic efficacy of zostavax vs. no vaccine in 60 adults with solid organ tumors before, during and after chemotherapy. the personnel performing the laboratory studies will be blinded to vaccine vs. no vaccine. in a pilot study of an fda approved vaccine that is being used within the parameters of the package insert and acip recommendations, placebo vaccine is not required to access our key primary immunologic endpoint.

Eligibility criteria:
inclusion criteria: * solid organ tumor patients that have at least 14 days between entry into the study with zostavax vaccination and initial therapy for their malignancy that will include chemotherapy alone or surgery with subsequent chemotherapy plus or minus radiation therapy * a plan for chemotherapy that at the onset at least an anticipated stop date within 3-6 months of our sample collection phase of the study exclusion criteria: * prior history of hz or shingles vaccine * systemic chemotherapy \< 3 months prior to enrollment * any history of hematologic malignancy, hiv/aids, hematopoietic stem cell transplant, or other cellular immunodeficiency state * those receiving immunomodulating drugs at the time of vaccination such as prednisone methotrexate, azathioprine, mercaptopurine, or other biologics including tnf-alpha inhibitors * widespread metastatic tumor with bone marrow involvement * indefinite duration palliative chemotherapy subjects * inability to communicate with the study staff or bring unable to consent for themselves * history of anaphylactic/anaphylactiod reaction to gelatin, neomycin, or other components of the vaccine

Keywords: solid tumor chemotherapy vaccine
a phase 3 study to evaluate efficacy and safety of al001 in frontotemporal dementia (infront-3)

Conditions: Frontotemporal Dementia

Summary: a phase 3 double blind, placebo controlled study evaluating the efficacy and safety of al001 in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.

this is a phase 3 double blind, placebo controlled study evaluating the efficacy and safety of al001 administered intravenously in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene. study completion marks the end of the open label extension period following the 96-week blinded portion of the study.

Eligibility criteria:
inclusion criteria: * persons with a progranulin gene mutation and at risk of developing ftd symptoms as evidenced by a biomarker, or persons with a progranulin gene mutation and diagnosed with ftd. * if symptomatic, one or more of the criteria for the diagnosis of possible behavioral variant ftd, or a diagnosis of primary progressive aphasia. * study partner who consents to study participation and who cares for/visits the participant daily for at least 5 hours per week. * written informed consent must be obtained and documented (from the participant or, where jurisdictions allow it, from their legal decision maker). exclusion criteria: * dementia due to a condition other than ftd including, but not limited to, alzheimer's disease, parkinson's disease, dementia with lewy bodies, huntington disease, or vascular dementia. * known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins. * current uncontrolled hypertension, diabetes mellitus or thyroid disease. clinically significant heart disease, liver disease or kidney disease. history or evidence of clinically significant brain disease other than ftd. * females who are pregnant or breastfeeding, or planning to conceive within the study period. * any experimental vaccine or gene therapy. * history of cancer within the last 5 years. * current use of anticoagulant medications (e.g., coumadin, heparinoids, apixaban). * residence in a skilled nursing facility, convalescent home, or long term care facility at screening; or requires continuous nursing care.
cardiomyopathy in steroid-resistant nephrotic syndrome: impact of focal segmental glomerulosclerosis

Conditions: Focal Segmental Glomerulosclerosis; Nephrotic Syndrome; Steroid Resistant Nephrotic Syndrome; Chronic Kidney Disease

Summary: the objective of this study is as follows: * perform genetic analysis to define the prevalence of each of the known gene mutations in an unselected cohort of patients with focal segmental glomerulosclerosis (fsgs) * perform a comprehensive assessment of cardiovascular status to determine the incidence of any cardiac abnormalities in patients with fsgs * determine if patients with mutations in specific proteins are more likely to have cardiovascular abnormalities * initiate long-term follow up in all patients to determine whether cardiac prognosis is related to any specific genetic abnormality

nephrotic syndrome is a frequent cause of chronic kidney disease in children. patients who are unresponsive to treatment with corticosteroids are further categorized as having steroid resistant nephrotic syndrome (srns). renal biopsy in srns patients often reveal the histological lesion of focal segmental glomerulosclerosis (fsgs). genetic research has identified mutations in specific podocyte proteins, which may lead to the development of steroid resistant nephrotic syndrome. in addition to being expressed in the fetal adult kidney, human podocin mrna is also expressed in the fetal heart tissue. multiple case reports have described an association between cardiac abnormalities and familial fsgs. these findings suggest that this gene may be involved in the pathogenesis of cardiac abnormalities seen in this population. the objectives of this study is to: * perform genetic analysis to define the prevalence of each of the known podocyte gene mutations in an unselected cohort of patients with fsgs * perform a comprehensive assessment of cardiovascular status to determine the incidence of any cardiac abnormalities in patients with fsgs * determine if patients with mutations in specific podocyte proteins are more likely to have cardiovascular abnormalities * initiate long-term follow up in all patients to determine whether cardiac prognosis is related to any specific genetic abnormality

Eligibility criteria:
inclusion criteria: * age 6 months - 21 years * srns, defined as failure to achieve remission in proteinuria after 4-6 weeks of daily steroid therapy in accord with iskdc guidelines * gfr \> 30 ml/min/1.73 m\^2 * renal disease diagnosed based on kidney biopsy exclusion criteria: * secondary fsgs * prior renal transplantation * congenital extra-renal abnormalities * significant structural cardiac abnormalities * pulmonary, hematologic, malignancy, or immune-related disease * inability to maintain adequate follow-up

Keywords: podocyte protein podocyte mutation
simplified conservative measures in managing morbidly adherent placenta in beni-suef university

Conditions: Placenta Accreta

Summary: to evaluate the efficacy of modified uterine artery ligation and myometrial compression as a conservative measure in improving the prognosis of the morbidly adherent placenta.

according to the international federation of gynecology and obstetrics (figo) guidelines, the principal surgical strategy to prevent excessive bleeding related to placenta accreta syndrome is to leave the placenta in situ and perform a primary peripartum hysterectomy at delivery. a hysterectomy may not be preferred by patients wishing to preserve fertility and is detrimental to multiple aspects of the pelvic floor, bowel, and physical functions. surgical principles in placenta accreta syndrome include avoiding disruption of the hypervascular placenta, stepwise devascularization, early and comprehensive blood product transfusion, and judicious use of interventional radiologic techniques such as vascular embolization. conservative management describes any approach whereby hysterectomy is avoided

Eligibility criteria:
inclusion criteria: * gestational age more than 28 weeks as determined by lmp and ultrasound. * placenta previa as confirmed by ultrasound. * clinically stable with no or mild vaginal bleeding. * no evidence of fetal compromise. * patient consent. exclusion criteria: * vaginal bleeding * medical disorders
evaluation of intestinal secretion of antibodies and auto-antibodies associated with crohn's disease

Conditions: Crohn's Disease

Summary: we propose to study the intestinal secretion of asca by evaluating them in biopsy culture supernatants from a cohort of patients suffering from cd (n=80) and a cohort of control patients (uc (n=40) and patients without ibd (n=40 )).

its diagnosis is based upon clinical, endoscopic and histological parameters but recent studies have shown that seric evaluation of immunological markers (anti-saccharomyces cerevisiae antibodies (asca), anti-neutrophil cytoplasmic auti-antibodies (anca)) could be useful. crohn's disease (cd) is an inflammatory bowel disease (ibd) of the young people. antibodies anti-chitobisoside carbohydrate (acca), anti-laminaribioside carbohydrate (alca) and anti-mannobioside carbohydrate (amca) have been described as new serological markers of cd.

Eligibility criteria:
inclusion criteria: * patients reached by disease of crohn * patients reached by hemorrhagic first side-colitis exclusion criteria: * forms ileales or ano-périneales pure of disease of crohn * indefinite colitis
lifestyle intervention trial in obese elderly

Conditions: Obesity

Summary: obesity causes frailty in obese older adults by exacerbating the age-related decline in physical function. however, appropriate management of obesity in older adults is controversial. weight loss without exercise could worsen frailty by accelerating the usual age-related decline in muscle and bone mass that leads to sarcopenia and osteopenia, respectively. because of the important problem of frailty in obese older adults, it is important to determine the most efficacious approach in reducing, or even reversing frailty in this population. the primary objective of this proposal is to evaluate which distinct type of physical exercise (resistance, aerobic, or combined resistance + aerobic) is most efficacious in preventing the weight-loss-induced reduction in muscle and bone mass and reversing frailty in obese older adults.


Eligibility criteria:
inclusion criteria: * 65-85 years old * obese men and women (bmi \> or equal to 30 kg/m2) * stable weight (±2 kg) during the last 6 mos. * must be sedentary (regular exercise \<1 h/wk or \<2 x/wk for the last 6 mos.) * be judged, during the initial screening, to be well motivated and reliable exclusion criteria: * any major chronic diseases * any condition or unstable diseases that would interfere with exercise or dietary restriction, in which exercise or dietary restriction are contraindicated, or that would interfere with interpretation of results that include but are not limited to: * cardiopulmonary disease (e.g., recent mi, unstable angina, stroke etc.) * severe orthopedic/musculoskeletal or neuromuscular impairments that would contraindicate participation in exercise * visual or hearing impairments that interfere with following directions * diagnosis of dementia * history of malignancy during the past 5 yr * recent use of bone acting drugs (e.g. use of estrogen, or androgen containing compound, raloxifene, calcitonin, parathyroid hormone during the past year or biphosphonates during the last two years) * individuals on insulin or with a fasting blood glucose of \> 140mg/dl, and/or a 2 hour post-glucose of \>250 mg/dl * bmd t-scores of \<-2.3 of the lumbar spine and proximal femur * serum creatinine \>2.0 mg/dl * no commitments, life situations or conditions that would interfere with their participation in the study